We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

134 hedge funds and large institutions have $270M invested in MoonLake Immunotherapeutics in 2025 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 33 increasing their positions, 41 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

130% more call options, than puts

Call options by funds: $33.1M | Put options by funds: $14.4M

3% more funds holding

Funds holding: 130 → 134 (+4)

9% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 45

20% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 41

33.32% less ownership

Funds ownership: 92.59% → 59.27% (-33%)

83% less funds holding in top 10

Funds holding in top 10: 6 → 1 (-5)

90% less capital invested

Capital invested by funds: $2.77B → $270M (-$2.5B)

Holders
134
Holders Change
+4
Holders Change %
+3.08%
% of All Funds
1.76%
Holding in Top 10
1
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-83.33%
% of All Funds
0.01%
New
49
Increased
33
Reduced
41
Closed
45
Calls
$33.1M
Puts
$14.4M
Net Calls
+$18.7M
Net Calls Change
+$16.8M

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$78.2M
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$66.5M
3
SSA
Schonfeld Strategic Advisors
New York
+$50.3M
4
Two Sigma Investments
Two Sigma Investments
New York
+$23.7M
5
IC
Ikarian Capital
Texas
+$22.7M

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$339M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$261M
3
ACA
Avoro Capital Advisors
New York
-$112M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$93.3M
5
Citadel Advisors
Citadel Advisors
Florida
-$84.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
HF
26
HRT Financial
New York
$1.03M +$7.47M +143,275 New
ClearBridge Investments
27
ClearBridge Investments
New York
$972K +$5.58M +107,069 +377%
RHJA
28
Rice Hall James & Associates
California
$967K -$390K -7,485 -5%
CS
29
Candriam SCA
Luxembourg
$958K -$583K -11,188 -8%
CCM
30
Catalio Capital Management
New York
$955K -$1.54M -29,465 -18%
Pictet Asset Management
31
Pictet Asset Management
Switzerland
$946K -$820K -15,730 -11%
BlackRock
32
BlackRock
New York
$899K -$10.5M -201,961 -62%
Vanguard Group
33
Vanguard Group
Pennsylvania
$862K -$32.6K -626 -0.5%
TD Asset Management
34
TD Asset Management
Ontario, Canada
$764K -$4.15M -79,542 -43%
CM
35
Caption Management
Oklahoma
$651K +$4.42M +84,831 +1,421%
Millennium Management
36
Millennium Management
New York
$639K +$4.65M +89,172 New
CIAM
37
Caitong International Asset Management
Hong Kong
$606K +$4.39M +84,177 +22,388%
UBS Group
38
UBS Group
Switzerland
$605K +$208K +3,997 +5%
CAM
39
Congress Asset Management
Massachusetts
$526K +$26.8K +514 +0.7%
SFM
40
Sphera Funds Management
Israel
$509K +$3.7M +71,010 New
Principal Financial Group
41
Principal Financial Group
Iowa
$509K +$3.7M +70,943 New
LPC
42
Lion Point Capital
New York
$484K +$3.52M +67,500 New
Manulife (Manufacturers Life Insurance)
43
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$468K -$2.33M -44,713 -41%
Geode Capital Management
44
Geode Capital Management
Massachusetts
$447K +$148K +2,832 +5%
WP
45
Woodline Partners
California
$436K -$13M -249,748 -80%
AIM
46
AXA Investment Managers
France
$436K +$3.17M +60,755 New
EGM
47
Engineers Gate Manager
New York
$422K +$3.07M +58,810 New
Simplex Trading
48
Simplex Trading
Illinois
$417K +$3.03M +58,229 New
Walleye Trading
49
Walleye Trading
New York
$385K +$2.8M +53,700 New
State Street
50
State Street
Massachusetts
$379K -$609K -11,678 -18%
1
2
3 4 5

MLTX Hedge Fund Activity: Q3 2025 in Review

134 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q3 2025, worth a combined $270M — down 90% from $2.77B a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new MLTX positions and 45 closed out — a net gain of 4 holders — while 33 added to existing stakes and 41 trimmed.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $78.2M. The largest seller was Cormorant Asset Management, cutting an estimated $339M.

  • 134 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q3 2025, up from 130 in Q2 2025.
  • Funds reported $270M of MoonLake Immunotherapeutics stock for Q3 2025, down 90% quarter-over-quarter.
  • 49 funds opened new MoonLake Immunotherapeutics positions in Q3 2025 and 45 closed out, a net change of +4 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q3 2025 was Adage Capital Partners, an estimated $78.2M added.
  • The largest MoonLake Immunotherapeutics seller in Q3 2025 was Cormorant Asset Management, an estimated $339M sold.

Based on aggregated 13F filings for Q3 2025.